167 related articles for article (PubMed ID: 17609951)
21. Exploiting the role of endogenous lymphoid-resident dendritic cells in the priming of NKT cells and CD8+ T cells to dendritic cell-based vaccines.
Petersen TR; Sika-Paotonu D; Knight DA; Simkins HM; Hermans IF
PLoS One; 2011 Mar; 6(3):e17657. PubMed ID: 21483862
[TBL] [Abstract][Full Text] [Related]
22. Tobacco mosaic virus efficiently targets DC uptake, activation and antigen-specific T cell responses in vivo.
Kemnade JO; Seethammagari M; Collinson-Pautz M; Kaur H; Spencer DM; McCormick AA
Vaccine; 2014 Jul; 32(33):4228-33. PubMed ID: 24923637
[TBL] [Abstract][Full Text] [Related]
23. The immunogenicity of dendritic cell-derived exosomes.
Quah BJ; O'Neill HC
Blood Cells Mol Dis; 2005; 35(2):94-110. PubMed ID: 15975838
[TBL] [Abstract][Full Text] [Related]
24. Augmentation of antitumor immune responses after adoptive transfer of bone marrow derived from donors immunized with tumor lysate-pulsed dendritic cells.
Asavaroengchai W; Kotera Y; Koike N; Pilon-Thomas S; Mulé JJ
Biol Blood Marrow Transplant; 2004 Aug; 10(8):524-33. PubMed ID: 15282530
[TBL] [Abstract][Full Text] [Related]
25. Transfection of immature murine bone marrow-derived dendritic cells with the granulocyte-macrophage colony-stimulating factor gene potently enhances their in vivo antigen-presenting capacity.
Curiel-Lewandrowski C; Mahnke K; Labeur M; Roters B; Schmidt W; Granstein RD; Luger TA; Schwarz T; Grabbe S
J Immunol; 1999 Jul; 163(1):174-83. PubMed ID: 10384114
[TBL] [Abstract][Full Text] [Related]
26. [Anti-metastatic effect of vascular endothelial growth factor receptor 2 extracellular domain gene-modified dendritic cell vaccination in murine model with experimental pulmonary metastasis].
Pan JP; Weng YS; Wu QQ
Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):646-9. PubMed ID: 17274366
[TBL] [Abstract][Full Text] [Related]
27. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.
Oba T; Makino K; Kajihara R; Yokoi T; Araki R; Abe M; Minderman H; Chang AE; Odunsi K; Ito F
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049930
[TBL] [Abstract][Full Text] [Related]
28. Tumor-induced interleukin 10 suppresses the ability of splenic dendritic cells to stimulate CD4 and CD8 T-cell responses.
Yang AS; Lattime EC
Cancer Res; 2003 May; 63(9):2150-7. PubMed ID: 12727833
[TBL] [Abstract][Full Text] [Related]
29. Migration patterns of dendritic cells in the mouse. Traffic from the blood, and T cell-dependent and -independent entry to lymphoid tissues.
Kupiec-Weglinski JW; Austyn JM; Morris PJ
J Exp Med; 1988 Feb; 167(2):632-45. PubMed ID: 3258009
[TBL] [Abstract][Full Text] [Related]
30. Anatomic location defines antigen presentation by dendritic cells to T cells in response to intravenous soluble antigens.
Chung Y; Chang JH; Kim BS; Lee JM; Kim HY; Kang CY
Eur J Immunol; 2007 Jun; 37(6):1453-62. PubMed ID: 17474148
[TBL] [Abstract][Full Text] [Related]
31. Conditional interleukin-12 gene therapy promotes safe and effective antitumor immunity.
Komita H; Zhao X; Katakam AK; Kumar P; Kawabe M; Okada H; Braughler JM; Storkus WJ
Cancer Gene Ther; 2009 Dec; 16(12):883-91. PubMed ID: 19444303
[TBL] [Abstract][Full Text] [Related]
32. The lymphoid past of mouse plasmacytoid cells and thymic dendritic cells.
Corcoran L; Ferrero I; Vremec D; Lucas K; Waithman J; O'Keeffe M; Wu L; Wilson A; Shortman K
J Immunol; 2003 May; 170(10):4926-32. PubMed ID: 12734335
[TBL] [Abstract][Full Text] [Related]
33. Lentiviral vector-mediated autonomous differentiation of mouse bone marrow cells into immunologically potent dendritic cell vaccines.
Koya RC; Kimura T; Ribas A; Rozengurt N; Lawson GW; Faure-Kumar E; Wang HJ; Herschman H; Kasahara N; Stripecke R
Mol Ther; 2007 May; 15(5):971-80. PubMed ID: 17375074
[TBL] [Abstract][Full Text] [Related]
34. Bone marrow-derived dendritic cells pulsed with a tumor-specific peptide elicit effective anti-tumor immunity against intracranial neoplasms.
Okada H; Tahara H; Shurin MR; Attanucci J; Giezeman-Smits KM; Fellows WK; Lotze MT; Chambers WH; Bozik ME
Int J Cancer; 1998 Oct; 78(2):196-201. PubMed ID: 9754652
[TBL] [Abstract][Full Text] [Related]
35. Enhancement of DC vaccine potency by activating the PI3K/AKT pathway with a small interfering RNA targeting PTEN.
Kim JH; Kang TH; Noh KH; Kim SH; Lee YH; Kim KW; Bae HC; Ahn YH; Choi EY; Kim JS; Lee KM; Kim TW
Immunol Lett; 2010 Nov; 134(1):47-54. PubMed ID: 20727912
[TBL] [Abstract][Full Text] [Related]
36. Dendritic cells matured by inflammation induce CD86-dependent priming of naive CD8+ T cells in the absence of their cognate peptide antigen.
Maroof A; Beattie L; Kirby A; Coles M; Kaye PM
J Immunol; 2009 Dec; 183(11):7095-103. PubMed ID: 19917700
[TBL] [Abstract][Full Text] [Related]
37. Impaired ability of MHC class II-/- dendritic cells to provide tumor protection is rescued by CD40 ligation.
Hermans IF; Ritchie DS; Daish A; Yang J; Kehry MR; Ronchese F
J Immunol; 1999 Jul; 163(1):77-81. PubMed ID: 10384102
[TBL] [Abstract][Full Text] [Related]
38. Lipopolysaccharide modulation of dendritic cells is insufficient to mature dendritic cells to generate CTLs from naive polyclonal CD8+ T cells in vitro, whereas CD40 ligation is essential.
Kelleher M; Beverley PC
J Immunol; 2001 Dec; 167(11):6247-55. PubMed ID: 11714787
[TBL] [Abstract][Full Text] [Related]
39. [Immunotherapy against tumor with dendritic cell sensitized by necrotic tumor tissue after microwave coagulation therapy].
Yao LC; Yang RJ
Zhonghua Yi Xue Za Zhi; 2007 Sep; 87(36):2552-6. PubMed ID: 18067832
[TBL] [Abstract][Full Text] [Related]
40. Potent in vivo anti-tumor activity of isolated CD62L(low) lymph node cells sensitized in vivo with tumor lysate-pulsed DC-based vaccines.
Liu Z; Fan H; Wu Y; Chen B
Cytotherapy; 2005; 7(4):353-62. PubMed ID: 16162457
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
